CSIO yields 0.67% · PFE yields 6.20%● Live data
📍 PFE pulled ahead of the other in Year 8
Combined, CSIO + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CSIO + PFE for your $10,000?
CSIO invests primarily in a concentrated portfolio of US and international infrastructure companies. Security selection is based on a value-oriented, bottom-up research process, evaluating firms on financial strength, management quality, industry positioning, and valuation metrics such as price/earnings, price/cash flow, dividend yield, and earnings growth. Eligible company exposure ranges from utilities, energy transport, communications networks, transportation systems, social infrastructure, and related suppliers, with up to 25% allocated to emerging markets. While CSIOs focus is common stocks, the fund may also hold preferred securities, hybrids, PIPEs, REIT-structured infrastructure assets, IPOs, and up to 20% in fixed-income securities. The fund does not target specific ESG outcomes but considers relevant ESG factors when assessing opportunities. Derivatives and currency hedging may be used mainly for risk management purposes.
Full CSIO Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.